PL2567690T3 - Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów - Google Patents

Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów

Info

Publication number: PL2567690T3
Authority: PL; Poland
Prior art keywords: amisulpride; vomiting; induced nausea; treating chemotherapy; chemotherapy
Prior art date: 2010-03-11

Application number

PL12188047T

Other languages

English (en)

Inventor

Julian Clive Gilbert

Robert William Gristwood

Nicola Cooper

Gabriel Fox

Original Assignee

Acacia Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-11

Filing date

2011-03-10

Publication date

2014-11-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2567690(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-10 Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd

2014-11-28 Publication of PL2567690T3 publication Critical patent/PL2567690T3/pl

Links

206010047700 Vomiting Diseases 0.000 title 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 title 1
229960003036 amisulpride Drugs 0.000 title 1
238000002512 chemotherapy Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Emergency Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL12188047T 2010-03-11 2011-03-10 Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów PL2567690T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1004020.2A GB201004020D0 (en)	2010-03-11	2010-03-11	New therapeutic use
EP11709793.1A EP2544657B1 (en)	2010-03-11	2011-03-10	Use of amisulpride for treating post-operative nausea and vomiting
EP12188047.0A EP2567690B1 (en)	2010-03-11	2011-03-10	Use of amisulpride for treating chemotherapy-induced nausea and vomiting

Publications (1)

Publication Number	Publication Date
PL2567690T3 true PL2567690T3 (pl)	2014-11-28

Family

ID=42136792

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL11709793T PL2544657T3 (pl)	2010-03-11	2011-03-10	Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
PL12188047T PL2567690T3 (pl)	2010-03-11	2011-03-10	Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
PL14173186T PL2796171T3 (pl)	2010-03-11	2011-03-10	Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL11709793T PL2544657T3 (pl)	2010-03-11	2011-03-10	Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL14173186T PL2796171T3 (pl)	2010-03-11	2011-03-10	Zastosowania amisulprydu w leczeniu nudności i wymiotów wywołanych przez opiat

Country Status (26)

Country	Link
US (12)	US9084765B2 (pl)
EP (3)	EP2796171B1 (pl)
JP (2)	JP5886213B2 (pl)
KR (1)	KR101738201B1 (pl)
CN (1)	CN102892407B (pl)
AU (1)	AU2011225898B2 (pl)
BR (1)	BR112012022746B1 (pl)
CA (1)	CA2792392C (pl)
CY (3)	CY1115485T1 (pl)
DK (3)	DK2796171T3 (pl)
EA (1)	EA030335B1 (pl)
ES (3)	ES2496099T3 (pl)
GB (1)	GB201004020D0 (pl)
HR (3)	HRP20140744T1 (pl)
HU (1)	HUE037088T2 (pl)
IL (1)	IL221746A (pl)
LT (1)	LT2796171T (pl)
MX (3)	MX2012010411A (pl)
NO (1)	NO2796171T3 (pl)
NZ (1)	NZ602279A (pl)
PL (3)	PL2544657T3 (pl)
PT (3)	PT2544657E (pl)
RS (3)	RS53466B (pl)
SI (3)	SI2796171T1 (pl)
SM (3)	SMT201800188T1 (pl)
WO (1)	WO2011110854A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201004020D0 (en)	2010-03-11	2010-04-21	Acacia Pharma Ltd	New therapeutic use
CN104435861A (zh) *	2014-12-22	2015-03-25	济南伟传信息技术有限公司	一种治疗妊娠剧吐的茶
GB201506116D0 (en)	2015-04-10	2015-05-27	Acacia Pharma Ltd	Kit and combination therapy for nausea and vomiting
US10761020B2 (en)	2015-09-02	2020-09-01	California Institute Of Technology	Method and apparatus for the spectroscopic detection of low concentrations of hydrogen sulfide gas
GB201618425D0 (en) *	2016-11-01	2016-12-14	Acacia Pharma Ltd	method
GB201702250D0 (en) *	2017-02-10	2017-03-29	Acacia Pharma Ltd	Method
MX2020005517A (es)	2017-12-05	2020-11-09	Sunovion Pharmaceuticals Inc	Formas cristalinas y metodos de produccion de las mismas.
US10369134B2 (en)	2017-12-05	2019-08-06	Sunovion Pharmaceuticals Inc.	Nonracemic mixtures and uses thereof
WO2020247603A1 (en) *	2019-06-04	2020-12-10	Sunovion Pharmaceuticals Inc.	Modified release formulations and uses thereof
WO2020247627A1 (en)	2019-06-04	2020-12-10	Sunovion Pharmaceuticals Inc.	Modified release formulations and uses thereof
EP4175631A1 (en)	2020-07-06	2023-05-10	Acacia Pharma Ltd	Therapy of post-operative nausea and vomiting
EP4496797A1 (en)	2022-03-21	2025-01-29	Gasherbrum Bio, Inc.	5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
US20250250269A1 (en)	2022-04-14	2025-08-07	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
JP2026501171A (ja)	2022-12-15	2026-01-14	ガシャーブラム・バイオ・インコーポレイテッド	Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態
EP4638455A1 (en)	2022-12-22	2025-10-29	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
EP4638440A1 (en)	2022-12-22	2025-10-29	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
AU2024222719A1 (en)	2023-02-16	2025-08-21	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
US20250019389A1 (en)	2023-06-30	2025-01-16	Gasherbrum Bio, Inc.	Heterocyclic agonists
TW202521528A (zh)	2023-07-13	2025-06-01	美商雅空嘉閣生物公司	化合物、組合物及方法
WO2025015269A1 (en)	2023-07-13	2025-01-16	Aconcagua Bio, Inc.	Compounds, compositions, and methods
WO2025045208A1 (en)	2023-08-31	2025-03-06	Gasherbrum Bio, Inc.	Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en)	2023-12-20	2025-06-26	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
WO2025171340A1 (en)	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en)	2024-02-08	2025-08-14	Aconcagua Bio, Inc.	Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025189141A1 (en)	2024-03-08	2025-09-12	Annapurna Bio, Inc.	Methods for treating obesity and increasing weight loss
WO2026041075A1 (en)	2024-08-21	2026-02-26	Gasherbrum Bio, Inc.	Gpl-1 agonists
WO2026051998A1 (en)	2024-09-04	2026-03-12	Aconcagua Bio, Inc.	Compounds, compositions, and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2415099A1 (fr) *	1978-01-20	1979-08-17	Ile De France	Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
US6169094B1 (en) *	1998-07-14	2001-01-02	Sanofi-Synthelabo	Compositions of (S) (-)-amisulpride
DE10163421A1 (de) *	2001-12-21	2003-07-31	Gruenenthal Gmbh	Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
DE102005013726A1 (de) *	2005-03-22	2006-09-28	Grünenthal GmbH	Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) *	2005-04-04	2005-05-11	Merck Sharp & Dohme	New uses
WO2007067714A2 (en) *	2005-12-08	2007-06-14	The Mclean Hospital Corporation	Treatment of sequelae of psychiatric disorders
US20070190145A1 (en)	2006-01-27	2007-08-16	Eurand, Inc.	Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
WO2007096489A1 (fr) *	2006-02-17	2007-08-30	Trimaran Limited	Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) *	2007-02-02	2010-11-02	Copharms	Method of treating bipolar depression with a benzamide derivative
EP3090743A1 (en) *	2008-01-09	2016-11-09	Charleston Laboratories, Inc.	Pharmaceutical compositions for treating headache and eliminating nausea
US8138169B2 (en) *	2008-04-11	2012-03-20	Comgenrx, Inc.	Combination therapy for bipolar disorder
GB201004020D0 (en)	2010-03-11	2010-04-21	Acacia Pharma Ltd	New therapeutic use

2010
- 2010-03-11 GB GBGB1004020.2A patent/GB201004020D0/en not_active Ceased
2011
- 2011-03-10 SI SI201131446T patent/SI2796171T1/en unknown
- 2011-03-10 HU HUE14173186A patent/HUE037088T2/hu unknown
- 2011-03-10 PL PL11709793T patent/PL2544657T3/pl unknown
- 2011-03-10 ES ES12188047.0T patent/ES2496099T3/es active Active
- 2011-03-10 PT PT117097931T patent/PT2544657E/pt unknown
- 2011-03-10 NZ NZ602279A patent/NZ602279A/en unknown
- 2011-03-10 SI SI201130236T patent/SI2544657T1/sl unknown
- 2011-03-10 HR HRP20140744AT patent/HRP20140744T1/hr unknown
- 2011-03-10 LT LTEP14173186.9T patent/LT2796171T/lt unknown
- 2011-03-10 NO NO14173186A patent/NO2796171T3/no unknown
- 2011-03-10 RS RS20140410A patent/RS53466B/sr unknown
- 2011-03-10 ES ES11709793.1T patent/ES2496092T3/es active Active
- 2011-03-10 BR BR112012022746-7A patent/BR112012022746B1/pt active IP Right Grant
- 2011-03-10 EP EP14173186.9A patent/EP2796171B1/en active Active
- 2011-03-10 CN CN201180018552.XA patent/CN102892407B/zh not_active Ceased
- 2011-03-10 EP EP11709793.1A patent/EP2544657B1/en active Active
- 2011-03-10 KR KR1020127024111A patent/KR101738201B1/ko active Active
- 2011-03-10 JP JP2012556586A patent/JP5886213B2/ja active Active
- 2011-03-10 RS RS20140411A patent/RS53467B/sr unknown
- 2011-03-10 ES ES14173186.9T patent/ES2665418T3/es active Active
- 2011-03-10 SM SM20180188T patent/SMT201800188T1/it unknown
- 2011-03-10 EA EA201290833A patent/EA030335B1/ru unknown
- 2011-03-10 PL PL12188047T patent/PL2567690T3/pl unknown
- 2011-03-10 DK DK14173186.9T patent/DK2796171T3/en active
- 2011-03-10 WO PCT/GB2011/050472 patent/WO2011110854A2/en not_active Ceased
- 2011-03-10 MX MX2012010411A patent/MX2012010411A/es active IP Right Grant
- 2011-03-10 MX MX2015003664A patent/MX370629B/es unknown
- 2011-03-10 SI SI201130237T patent/SI2567690T1/sl unknown
- 2011-03-10 AU AU2011225898A patent/AU2011225898B2/en active Active
- 2011-03-10 PL PL14173186T patent/PL2796171T3/pl unknown
- 2011-03-10 DK DK12188047.0T patent/DK2567690T3/da active
- 2011-03-10 CA CA2792392A patent/CA2792392C/en active Active
- 2011-03-10 RS RS20180349A patent/RS57032B1/sr unknown
- 2011-03-10 DK DK11709793.1T patent/DK2544657T3/da active
- 2011-03-10 EP EP12188047.0A patent/EP2567690B1/en active Active
- 2011-03-10 PT PT121880470T patent/PT2567690E/pt unknown
- 2011-03-10 MX MX2019015396A patent/MX388787B/es unknown
- 2011-03-10 PT PT141731869T patent/PT2796171T/pt unknown
2012
- 2012-07-26 US US13/559,168 patent/US9084765B2/en active Active
- 2012-07-26 US US13/559,253 patent/US8686019B2/en active Active
- 2012-09-02 IL IL221746A patent/IL221746A/en active IP Right Grant
2014
- 2014-02-04 US US14/172,194 patent/US9119836B2/en active Active
- 2014-08-01 HR HRP20140745AT patent/HRP20140745T1/hr unknown
- 2014-08-14 CY CY20141100656T patent/CY1115485T1/el unknown
- 2014-08-14 CY CY20141100657T patent/CY1115487T1/el unknown
- 2014-09-10 SM SM201400127T patent/SMT201400127B/xx unknown
- 2014-09-10 SM SM201400126T patent/SMT201400126B/xx unknown
2015
- 2015-07-29 US US14/812,148 patent/US9545426B2/en active Active
- 2015-09-24 JP JP2015187057A patent/JP6279526B2/ja active Active
2016
- 2016-12-09 US US15/374,174 patent/US9889118B2/en active Active
2017
- 2017-10-23 US US15/790,481 patent/US10085970B2/en active Active
2018
- 2018-03-14 HR HRP20180436TT patent/HRP20180436T1/hr unknown
- 2018-04-18 CY CY20181100416T patent/CY1120170T1/el unknown
- 2018-08-20 US US16/105,268 patent/US10525033B2/en active Active
2019
- 2019-11-27 US US16/697,986 patent/US20200093792A1/en not_active Abandoned
2020
- 2020-09-08 US US17/013,987 patent/US20210228543A1/en not_active Abandoned
2022
- 2022-06-07 US US17/834,000 patent/US20220296570A1/en not_active Abandoned
2023
- 2023-01-11 US US18/095,612 patent/US12194022B2/en active Active
2024
- 2024-12-06 US US18/972,484 patent/US20250186394A1/en active Pending

Also Published As

Publication number	Publication date
EA030335B1 (ru)	2018-07-31
EA201290833A1 (ru)	2013-09-30
SMT201400127B (it)	2015-05-05
MX388787B (es)	2025-03-20
JP5886213B2 (ja)	2016-03-16
AU2011225898B2 (en)	2014-07-03
ES2496099T3 (es)	2014-09-18
HRP20180436T1 (hr)	2018-05-04
PL2796171T3 (pl)	2018-07-31
BR112012022746A2 (pt)	2016-07-05
US20250186394A1 (en)	2025-06-12
MX2019015396A (es)	2020-02-07
ES2496092T3 (es)	2014-09-18
US20150335616A1 (en)	2015-11-26
CN102892407B (zh)	2016-03-23
PT2567690E (pt)	2014-09-03
DK2796171T3 (en)	2018-05-07
RS53467B (sr)	2014-12-31
US20170087128A1 (en)	2017-03-30
LT2796171T (lt)	2018-05-10
NO2796171T3 (pl)	2018-06-30
US20200093792A1 (en)	2020-03-26
PL2544657T3 (pl)	2014-10-31
SI2796171T1 (en)	2018-05-31
US20210228543A1 (en)	2021-07-29
JP2016028090A (ja)	2016-02-25
ES2665418T3 (es)	2018-04-25
CY1120170T1 (el)	2018-12-12
US20130022689A1 (en)	2013-01-24
US10525033B2 (en)	2020-01-07
CA2792392A1 (en)	2011-09-15
EP2796171B1 (en)	2018-01-31
AU2011225898A1 (en)	2012-10-04
US9084765B2 (en)	2015-07-21
IL221746A (en)	2017-03-30
RS57032B1 (sr)	2018-05-31
CN102892407A (zh)	2013-01-23
EP2544657A2 (en)	2013-01-16
MX370629B (es)	2019-12-18
DK2567690T3 (da)	2014-08-11
JP6279526B2 (ja)	2018-02-14
EP2544657B1 (en)	2014-07-16
DK2544657T3 (da)	2014-08-11
MX2012010411A (es)	2012-11-30
KR20130045241A (ko)	2013-05-03
PT2796171T (pt)	2018-04-24
US9889118B2 (en)	2018-02-13
NZ602279A (en)	2014-08-29
EP2567690A1 (en)	2013-03-13
US20180353473A1 (en)	2018-12-13
US8686019B2 (en)	2014-04-01
US20230144973A1 (en)	2023-05-11
CY1115487T1 (el)	2017-01-04
EP2567690B1 (en)	2014-07-16
WO2011110854A3 (en)	2011-11-10
PT2544657E (pt)	2014-09-03
EP2796171A1 (en)	2014-10-29
US9119836B2 (en)	2015-09-01
CY1115485T1 (el)	2017-01-04
US12194022B2 (en)	2025-01-14
WO2011110854A2 (en)	2011-09-15
US20130022688A1 (en)	2013-01-24
CA2792392C (en)	2018-06-19
JP2013522181A (ja)	2013-06-13
HK1179152A1 (zh)	2013-09-27
SI2544657T1 (sl)	2014-12-31
HRP20140745T1 (hr)	2014-09-26
SI2567690T1 (sl)	2014-12-31
SMT201800188T1 (it)	2018-07-17
US20180042896A1 (en)	2018-02-15
HUE037088T2 (hu)	2018-08-28
US20140147517A1 (en)	2014-05-29
US10085970B2 (en)	2018-10-02
US9545426B2 (en)	2017-01-17
SMT201400126B (it)	2015-05-05
GB201004020D0 (en)	2010-04-21
BR112012022746B1 (pt)	2021-09-28
US20220296570A1 (en)	2022-09-22
KR101738201B1 (ko)	2017-05-19
HRP20140744T1 (hr)	2014-09-26
RS53466B (sr)	2014-12-31

Publication	Publication Date	Title
PL2567690T3 (pl)	2014-11-28	Zastosowanie amisulprydu do leczenia pooperacyjnych nudności i wymiotów
GB2513167B (en)	2016-03-02	Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
EP2603250A4 (en)	2018-03-21	Wound treatment and containment arrangement
PL2646446T3 (pl)	2015-10-30	Inhibitory bromodomeny i ich zastosowania
ZA201303605B (en)	2014-11-26	Compounds and methods for treating pain
EP2523630A4 (en)	2014-01-08	SYSTEMS AND METHODS FOR BARIATRIC THERAPY
GB201012175D0 (en)	2010-09-01	Procedure and mechanisms
GB201006079D0 (en)	2010-05-26	Surgical device and methods
EP2658478A4 (en)	2017-03-29	Improved surgical implant devices and methods for their manufacture and use
ZA201206257B (en)	2013-05-29	N-(imidazopyrimidin-7yl)-heteroarylamide derivatives and their use as pde10a inhibitors
EP2579819A4 (en)	2013-12-11	IMPLANT COMPONENTS AND METHOD
EP2542086A4 (en)	2013-09-04	COMPOUNDS AND ITS THERAPEUTIC USE
IL222227A0 (en)	2012-12-31	Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL222702A0 (en)	2012-12-31	Incontinence treatment
SG2014006068A (en)	2014-03-28	Isotopically-enriched boron-containing compounds, and methods of making and using same
ZA201300693B (en)	2015-10-28	Tube-feed packages and methods for using same
GB201012336D0 (en)	2010-09-08	Surgical device and procedure
EP2574172A4 (en)	2013-10-30	MATERIALS AND METHOD FOR TREATING INFLAMMATION
PL2616065T3 (pl)	2018-05-30	GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ
ZA201300036B (en)	2013-09-25	Banzamide derivatives and their use as hsp90 inhibitors
IL212760A0 (en)	2011-08-31	Internal and external disc shunts alleviate back pain
IL222479A0 (en)	2012-12-31	Devices and methods for tissue engineering
ZA201209666B (en)	2013-07-31	Salts and polymorhs of dexrabeprazole
EP2566483A4 (en)	2013-11-13	METHOD AND MEANS FOR IMPROVED WOUND HEALING
GB201011411D0 (en)	2010-08-18	Therapeutic compounds and their use